TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lifted its holdings in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) by 96.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,095 shares of the company’s stock after purchasing an additional 30,958 shares during the period. Cubist Systematic Strategies LLC owned about 0.12% of TScan Therapeutics worth $192,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Lynx1 Capital Management LP increased its stake in shares of TScan Therapeutics by 2.5% during the 4th quarter. Lynx1 Capital Management LP now owns 5,357,347 shares of the company’s stock worth $16,286,000 after purchasing an additional 132,747 shares in the last quarter. abrdn plc increased its stake in shares of TScan Therapeutics by 137.8% during the 4th quarter. abrdn plc now owns 883,704 shares of the company’s stock worth $2,686,000 after purchasing an additional 512,049 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of TScan Therapeutics by 108.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 280,028 shares of the company’s stock worth $851,000 after purchasing an additional 145,731 shares in the last quarter. Tocqueville Asset Management L.P. increased its stake in shares of TScan Therapeutics by 26.8% during the 4th quarter. Tocqueville Asset Management L.P. now owns 260,870 shares of the company’s stock worth $793,000 after purchasing an additional 55,140 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in shares of TScan Therapeutics by 54.4% during the 4th quarter. Bank of America Corp DE now owns 150,114 shares of the company’s stock worth $456,000 after purchasing an additional 52,903 shares in the last quarter. 82.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on TCRX shares. HC Wainwright dropped their price objective on shares of TScan Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 target price on shares of TScan Therapeutics in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $9.00 target price on shares of TScan Therapeutics in a research note on Tuesday, April 8th. Morgan Stanley reaffirmed an “overweight” rating and issued a $10.00 target price on shares of TScan Therapeutics in a research note on Friday, March 14th. Finally, Barclays lowered their target price on shares of TScan Therapeutics from $14.00 to $3.00 and set an “overweight” rating for the company in a research note on Friday, March 7th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $7.80.

TScan Therapeutics Stock Down 5.3%

Shares of TCRX opened at $1.24 on Monday. The firm has a market cap of $70.17 million, a PE ratio of -1.17 and a beta of 1.06. The company’s fifty day moving average is $1.43 and its two-hundred day moving average is $2.57. TScan Therapeutics, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $9.69. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.02. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. Analysts forecast that TScan Therapeutics, Inc. will post -1.12 earnings per share for the current year.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.